GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (FRA:3TP0) » Definitions » Beneish M-Score

Acerus Pharmaceuticals (FRA:3TP0) Beneish M-Score : 0.00 (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Acerus Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Acerus Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Acerus Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.


Acerus Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Acerus Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Beneish M-Score Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.74 -7.16 -5.32 1.22 -

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acerus Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Beneish M-Score falls into.



Acerus Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Acerus Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was €1.14 Mil.
Revenue was 0.778 + 0.708 + 0.71 + 0.653 = €2.85 Mil.
Gross Profit was 0.574 + 0.253 + 0.482 + 0.305 = €1.61 Mil.
Total Current Assets was €10.52 Mil.
Total Assets was €48.15 Mil.
Property, Plant and Equipment(Net PPE) was €0.62 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.23 Mil.
Selling, General, & Admin. Expense(SGA) was €17.02 Mil.
Total Current Liabilities was €15.61 Mil.
Long-Term Debt & Capital Lease Obligation was €46.57 Mil.
Net Income was -4.215 + -7.507 + -6.311 + -7.985 = €-26.02 Mil.
Non Operating Income was 3.065 + 0.162 + -0.107 + -0.637 = €2.48 Mil.
Cash Flow from Operations was -7.955 + -5.72 + -4.234 + -6.421 = €-24.33 Mil.
Total Receivables was €1.87 Mil.
Revenue was 0.499 + 0.425 + -5.015 + 0.223 = €-3.87 Mil.
Gross Profit was 0.083 + 0.388 + -5.175 + -0.473 = €-5.18 Mil.
Total Current Assets was €7.37 Mil.
Total Assets was €9.65 Mil.
Property, Plant and Equipment(Net PPE) was €0.55 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.71 Mil.
Selling, General, & Admin. Expense(SGA) was €17.29 Mil.
Total Current Liabilities was €10.39 Mil.
Long-Term Debt & Capital Lease Obligation was €12.64 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.142 / 2.849) / (1.869 / -3.868)
=0.400842 /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-5.177 / -3.868) / (1.614 / 2.849)
= / 0.566515
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (10.52 + 0.623) / 48.147) / (1 - (7.369 + 0.553) / 9.647)
=0.768563 / 0.178812
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.849 / -3.868
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.711 / (0.711 + 0.553)) / (0.234 / (0.234 + 0.623))
=0.5625 / 0.273046
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.018 / 2.849) / (17.291 / -3.868)
=5.973324 /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((46.569 + 15.607) / 48.147) / ((12.638 + 10.387) / 9.647)
=1.291378 / 2.386752
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-26.018 - 2.483 - -24.33) / 48.147
=-0.086631

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Acerus Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals (FRA:3TP0) Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals (FRA:3TP0) Headlines

No Headlines